Alto Neuroscience(NYSE) ANRO

Alto makes personalized medicines for people with mental health conditions. It uses brain tests and computer data to find the right drugs for specific patients. This helps doctors treat depression and other brain disorders more effectively.

Pipeline for Mental Health Care

• ALTO-207: Combination drug for treatment-resistant depression; uses pramipexole and an anti-nausea medicine to allow for higher dosages.
• ALTO-300: Investigational pill for major depressive disorder; identifies potential responders using an electroencephalogram, or EEG, which measures electrical activity in the brain.
• ALTO-101: Transdermal patch for cognitive issues in schizophrenia; delivers medicine through the skin to avoid nausea and stomach-related side effects.
• ALTO-100: Drug for bipolar depression; targets neuroplasticity, which refers to the brain's ability to adapt and form new connections.

Key Agreements and Acquisitions

• Acquired ALTO-207 and ALTO-208 from Chase Therapeutics Corporation in May 2025 to expand its psychiatry pipeline.
• Entered an 11.7 million dollar funding agreement with The Wellcome Trust Limited in July 2024 to support bipolar depression trials.
• Partnered with MedRx Co., Ltd. in September 2023 to develop a proprietary skin patch for drug delivery.
• Licensed ALTO-101 from Sanofi in May 2021 for development in human therapeutic and diagnostic applications.
• Obtained exclusive rights to brain stimulation and imaging technology through a 2019 agreement with Stanford University.

What Sets the Platform Apart

The company uses machine learning to match patient biological data with specific drug candidates. This precision approach seeks to move psychiatry away from a trial-and-error method by using objective brain-based markers.

Current Financial Position

• Net income was -$16.2 million in Q4 2025, which deepened 6.5% from -$15.2 million in Q4 2024.
• Free cash flow reached -$11.5 million in Q4 2025, an improvement of 14.9% from -$13.5 million in Q4 2024.
• Operating income was -$17.1 million in Q4 2025, which worsened 0.3% from -$17.0 million in Q4 2024.
• Market capitalization reached $568.2 million in Q4 2025, up 397.8% from $114.2 million in Q4 2024.

The Long-Term View

Alto has evolved into a clinical-stage firm with seven assets addressing conditions like depression and schizophrenia. Its growth relies on proving that biological markers can successfully predict how individual patients will respond to psychiatric treatments.